1. Home
  2. CHT vs NTRA Comparison

CHT vs NTRA Comparison

Compare CHT & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chunghwa Telecom Co. Ltd.

CHT

Chunghwa Telecom Co. Ltd.

HOLD

Current Price

$42.76

Market Cap

32.4B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$215.92

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHT
NTRA
Founded
1996
2003
Country
US
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.4B
32.9B
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
CHT
NTRA
Price
$42.76
$215.92
Analyst Decision
Strong Buy
Analyst Count
0
14
Target Price
N/A
$253.79
AVG Volume (30 Days)
190.9K
976.8K
Earning Date
01-01-0001
04-06-2026
Dividend Yield
3.03%
N/A
EPS Growth
N/A
59.52
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$3.64
$34.18
Revenue Next Year
$1.67
$16.69
P/E Ratio
$26.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.03
$125.38
52 Week High
$47.03
$256.36

Technical Indicators

Market Signals
Indicator
CHT
NTRA
Relative Strength Index (RSI) 58.42 44.44
Support Level $41.20 $204.04
Resistance Level $43.24 $213.96
Average True Range (ATR) 0.66 9.41
MACD 0.08 -0.70
Stochastic Oscillator 77.45 47.54

Price Performance

Historical Comparison
CHT
NTRA

About CHT Chunghwa Telecom Co. Ltd.

Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company segment consists of Consumer Business, Enterprise Business, International Business, and Others. The company generates the majority of its revenue from the Consumer Business segment. The consumer Business segment generates revenue from Mobile services, Fixed-line services, Sales, and others.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: